ABC · 5d
Zepbound leads to more weight loss than Wegovy, Eli Lilly says
Zepbound, a drug with the main active ingredient tirzepatide, was found to be more helpful in helping people lose weight than Wegovy, a drug with the main active ingredient semaglutide, according to new data released Wednesday by Eli Lilly, the maker of Zepbound.
AOL · 4d
Zepbound Leads to More Weight Loss Than Wegovy in Head-to-Head Clinical Trial
Drug manufacturer Eli Lilly says their drug Zepbound is more effective than Wegovy for long-term weight loss. Results from a clinical trial show 20% of participants who took Zepbound achieved significant weight loss compared to nearly 14% of participants who took Wegovy.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results